Clinical Trial Update: A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for BB-401 in recurrent or metastatic head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• BB-401

Snippet

Sponsor: Benitec Biopharma, Inc. | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED